|
|
Blood, 1 October 2007, Vol. 110, No. 7, pp. 2242-2249.
Prepublished online as a Blood First Edition Paper on May 11, 2007; DOI 10.1182/blood-2007-03-066936.
 Previous Article | Table of Contents | Next Article 
PERSPECTIVE
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare1,2,
Christopher A. Eide2, and
Michael W. N. Deininger2
1 Howard Hughes Medical Institute, Chevy Chase, MD;
2 Oregon Health & Science University Cancer Institute, Portland, OR
Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance. We also provide a perspective on how the second-line Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, especially in relation to specific KD mutations. We discuss the growing importance of the multi-inhibitor–resistant 315T>I mutant and the therapeutic potential that a 315T>I inhibitor would have. Last, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. D. Press, S. G. Willis, J. Laudadio, M. J. Mauro, and M. W. N. Deininger
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
Blood,
September 24, 2009;
114(13):
2598 - 2605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, D. Jones, H. M. Kantarjian, S. O'Brien, C. Tam, C. Koller, J. A. Burger, G. Borthakur, W. G. Wierda, and J. Cortes
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Blood,
September 3, 2009;
114(10):
2037 - 2043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ernst, F. X. Gruber, O. Pelz-Ackermann, J. Maier, M. Pfirrmann, M. C. Muller, I. Mikkola, K. Porkka, D. Niederwieser, A. Hochhaus, et al.
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
Haematologica,
September 1, 2009;
94(9):
1227 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brehme, O. Hantschel, J. Colinge, I. Kaupe, M. Planyavsky, T. Kocher, K. Mechtler, K. L. Bennett, and G. Superti-Furga
Charting the molecular network of the drug target Bcr-Abl
PNAS,
May 5, 2009;
106(18):
7414 - 7419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, et al.
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Blood,
April 9, 2009;
113(15):
3428 - 3434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, J. E. Cortes, and H. M. Kantarjian
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Mayo Clin. Proc.,
February 1, 2009;
84(2):
161 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Jones, S. Kamel-Reid, D. Bahler, H. Dong, K. Elenitoba-Johnson, R. Press, N. Quigley, P. Rothberg, D. Sabath, D. Viswanatha, et al.
Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia: A Report of the Association for Molecular Pathology
J. Mol. Diagn.,
January 1, 2009;
11(1):
4 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. O'Hare and M. W. Deininger
Toward a Cure For Chronic Myeloid Leukemia
Clin. Cancer Res.,
December 15, 2008;
14(24):
7971 - 7974.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker
Translation of the Philadelphia chromosome into therapy for CML
Blood,
December 15, 2008;
112(13):
4808 - 4817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, and J. Cortes
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
Blood,
December 15, 2008;
112(13):
4839 - 4842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.T. Williams and C.J. Sherr
The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias
Cold Spring Harb Symp Quant Biol,
November 26, 2008;
(2008)
sqb.2008.73.039v2.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, et al.
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Blood,
November 15, 2008;
112(10):
3965 - 3973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Campbell, E. D. Pleasance, P. J. Stephens, E. Dicks, R. Rance, I. Goodhead, G. A. Follows, A. R. Green, P. A. Futreal, and M. R. Stratton
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
PNAS,
September 2, 2008;
105(35):
13081 - 13086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, and S. Grant
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Blood,
August 1, 2008;
112(3):
793 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Kenealy, C. B. Christenson, and C. B. Williams
Current Therapies for Chronic Myeloid Leukemia
Journal of Pharmacy Practice,
April 1, 2008;
21(2):
116 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. S. Khorashad, D. Milojkovic, P. Mehta, M. Anand, S. Ghorashian, A. G. Reid, V. De Melo, A. Babb, H. de Lavallade, E. Olavarria, et al.
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
Blood,
February 15, 2008;
111(4):
2378 - 2381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, F. Pane, and G. Saglio
Monitoring treatment of chronic myeloid leukemia
Haematologica,
February 1, 2008;
93(2):
161 - 169.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Haematologica,
February 1, 2008;
93(2):
186 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Deininger
Milestones and Monitoring in Patients with CML Treated with Imatinib
Hematology,
January 1, 2008;
2008(1):
419 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Saglio, F. Pane, and G. Martinelli
State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia
ASCO Educational Book,
January 1, 2008;
2008(1):
313 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W.N. Deininger
Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells
ASCO Educational Book,
January 1, 2008;
2008(1):
318 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood,
October 15, 2007;
110(8):
2828 - 2837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Williams, W. den Besten, and C. J. Sherr
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
Genes & Dev.,
September 15, 2007;
21(18):
2283 - 2287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
